Adient's fiscal third quarter arrived with the automotive seating supplier in the middle of its longest-running argument with the market: the world's largest independent seat maker grew sales steadily out of a weak base, yet its adjusted profit barely budged, and investors kept discounting that gap. The quarter is the clearest statement yet of the problem. Net sales rose 5% to $3.93 billion on stronger Americas and Asia production, but adjusted EBITDA was essentially flat at $225 million - indistinguishable from the $226 million of a year earlier - so the adjusted EBITDA margin slipped to 5.7% from 6.0%. Volume came back; the profit it should carry did not convert.
There are two ways to read this, and they point in different directions. The first is mostly accounting: growth was flattered by a ~$52 million financial receivable the company booked after the U.S. Supreme Court nullified certain IEEPA tariffs, most of which it expects to pass back to customers - the quarter's single largest "benefit" was an air pocket, not economics. The second is operational and more worrying: in Asia, the region supplying the growth, net sales climbed 12% while adjusted EBITDA fell to $107 million from $113 million as newly won local-OEM business in China carries lower margins, exactly the mix shift management flagged. Americas did the real work, lifting adjusted EBITDA 12% on volume, tariff refunds, and pricing. Strip the comparisons and the quarter says the same thing the last several did - top line expanding, the adjusted EBITDA rate stuck in the mid-single digits.
The one number above the noise: adjusted diluted EPS rose to $0.48 from $0.45 - on flat adjusted net income, thanks to a shrinking share count, with management buying back $30 million of stock in the quarter at an average $22.49 a share it no longer has to pay. The stock now trades near $19, roughly 15% below that average execution price. The thesis is that Adient's growth eventually converts: that volume leads margin, that EMEA's softness bottoms, and that the buyback backstops a chunky margin and cash story while the market waits. The tests are specific and measurable - whether the adjusted EBITDA rate rebuilds toward the mid-teens Asia used to print, and whether the margin gap between volume and profit narrows. Those are the clocks the next reports read.